Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00860782
Other study ID # 20080278
Secondary ID U54HL090569U54HL
Status Completed
Phase N/A
First received
Last updated
Start date August 2008
Est. completion date May 2016

Study information

Verified date July 2021
Source University of Miami
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Children with sickle cell disease (SCD) are at risk for central nervous system (CNS) complications, which may affect academic achievement. This study will evaluate an educational support program for parents that aims to improve academic achievement in children with SCD.


Description:

SCD is an inherited blood disorder that is caused by an abnormal type of hemoglobin-the protein in red blood cells that carries oxygen to tissues. Symptoms include anemia, infections, organ damage, and intense episodes of pain, which are called "sickle cell crises." Children with SCD are also at risk for a variety of CNS complications, including various types of stroke and increased blood flow to the brain. These conditions affect neuropsychological performance and academic achievement. In children with SCD, there may also be a relationship between CNS complications, behavioral problems, family environment stressors, and pain symptoms. For example, children with SCD-related CNS complications have a higher risk of developing behavioral problems than children without SCD. In turn, behavioral problems are associated with high levels of family conflict and can be a significant stressor for families coping with SCD. This kind of stress can then lead to increased difficulty in dealing with SCD symptoms, particularly pain, for the child. This study will evaluate an educational support program for parents of children with SCD, conducted either once a year or four times a year, in terms of the program's effect on children's academic achievement. In addition, study researchers will also evaluate the program's effect on behavioral difficulties, pain frequency, and the family environment. This study will enroll children with HbSS (sickle cell anemia) or HbSb-thal (hemoglobin S beta thalassemia) SCD. Parents or caregivers of participants will be randomly assigned to attend the educational support program meetings either once a year or four times a year for 2 years. The educational meetings with the parent/caregiver will be 45 minutes long and will cover the following four main areas: 1. Provide education regarding the learning issues often seen with children with SCD 2. Provide information regarding special education services in the school system and how the parent can obtain academic support for his/her child 3. Provide information on how to assist the child to better manage homework 4. Evaluate the child's current level of pain and how pain may affect school attendance There will be three evaluation timepoints. At baseline and Year 3, children will undergo a neurodevelopmental evaluation, including academic achievement tests. The parent and child will complete questionnaires on emotional and behavioral functioning, stress levels, and family functioning. At Year 2, the children will complete academic achievement tests, and the questionnaires for the parent and child will be repeated.


Recruitment information / eligibility

Status Completed
Enrollment 73
Est. completion date May 2016
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender All
Age group 6 Years to 12 Years
Eligibility Inclusion Criteria: - Children with either HbSS (sickle cell anemia) or HbSß-thal (hemoglobin S beta thalassemia) who are between 6 and 12 years of age - Child's parent or primary caregiver agrees to participate in the study Exclusion Criteria: - Child is monolingual in a language other than English and cannot complete standardized testing in English - Parent or caregiver of the child is not fluent in English or Spanish - Child has some other developmental disability not related to SCD. This would include Down's syndrome, autism, pervasive developmental disability, cerebral palsy, seizure disorder, consequences of severe prematurity, or a documented closed head injury that resulted in loss of consciousness. - Child has been diagnosed with a significant mental health disorder that is not responsive to behavioral or medical management. This includes severe depression, schizophrenia, or bipolar disorder. Children whose mental health problem is effectively treated are eligible for participation.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Parent Educational Support
Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.

Locations

Country Name City State
United States Mailman Center for Child Development Miami Florida

Sponsors (2)

Lead Sponsor Collaborator
University of Miami National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Academic achievement as measured by the Woodcock Johnson Tests of Achievement, Third Edition Performance on standardized measure of academic achievement, M=100, SD=15 Measured at baseline and Years 2 and 3
Secondary Child's emotional and behavioral functioning, parental stress, and family functioning Standardized parent report quesionnaires of child adjustment, parent stress, and family function Measured at baseline and Years 2 and 3
See also
  Status Clinical Trial Phase
Recruiting NCT06078696 - Siplizumab for Sickle Cell Disease Transplant Phase 1/Phase 2
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT02561312 - Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
Completed NCT00890396 - Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
Completed NCT00059293 - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Completed NCT00005277 - Cooperative Study of The Clinical Course of Sickle Cell Disease N/A
Active, not recruiting NCT04170348 - Daily Vitamin D for Sickle-cell Respiratory Complications Phase 2
Completed NCT04584528 - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease N/A
Recruiting NCT02286154 - Therapeutic Response Evaluation and Adherence Trial (TREAT) N/A
Completed NCT02857023 - Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease N/A
Withdrawn NCT01925001 - Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis Phase 2
Terminated NCT00122980 - Stroke With Transfusions Changing to Hydroxyurea Phase 3
Completed NCT00246077 - Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport N/A
Completed NCT00094887 - Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises Phase 2
Completed NCT00035763 - Pain in Sickle Cell Epidemiologic Study N/A
Terminated NCT04091737 - CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease Phase 1
Completed NCT00005300 - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease N/A
Recruiting NCT04351698 - SMILES: Study of Montelukast in Sickle Cell Disease Phase 2/Phase 3
Not yet recruiting NCT06290401 - A Socio-ecological Approach for Improving Self-management in Adolescents With SCD Phase 2